SureTrader
Home > Boards > US Listed > Biotechs >

BioTime, Inc. (BTX)

BTX RSS Feed
Add BTX Price Alert      Hide Sticky   Hide Intro
Moderator: ahab333
Search This Board: 
Last Post: 2/22/2018 9:35:27 AM - Followers: 69 - Board type: Free - Posts Today: 0

 

BioTime, Inc.  (BTX)

 

 
 

 

http://www.biotimeinc.com/

 

 

 

Company Information:

BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502

Phone: 510-521-3390
      Fax: 510-521-3389

 

CIK

0000876343

 

 

BioTime, Inc. (NYSE AMEX: BTX) is a biotechnology company engaged in two areas of biomedical research and product development:

  • Stem cell technology and products for use in regenerative medicine.  These products and technologies are being developed and marketed by our wholly owned subsidiary Embryome Sciences, Inc.
  • Blood plasma volume expanders and related technology for use in surgery, emergency trauma treatment and other applications.  Our lead product is Hextend® which is being marketed by Hospira, Inc. and CJ CheilJedang Corp. under exclusive licenses from us

 

The Potential of Regenerative Medicine

Regenerative medicine refers to therapies based on human embryonic stem ("hES") cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The great scientific and public interest in regenerative medicine lies in the potential of hES cells to transform into any cell type of the human body. hES cells therefore show considerable potential as a source of new therapies for a host of currently-incurable diseases such as: diabetes, stroke, Alzheimer's and Parkinson's disease, heart failure, arthritis, muscular dystrophy, spinal cord injury, macular degeneration, hearing loss, kidney and liver failure, as well as many other disorders that may be treated by replacing diseased or damaged organ tissues. In response to the unusual potential of the field, the State of California has allocated $3 billion over the next 10 years to fund basic research, and President Obama has lifted previous restrictions for federal funding of stem cell research.

Led by Dr. Michael West, considered by many to be a founding father of the stem cell industry, BioTime has assembled an array of products and associated intellectual property that give it the potential to be a leader in this exciting new field of medicine.

We are implementing a near-term revenues strategy in the regenerative medicine field by seeking to develop and market advanced hES products and technology that can be used by researchers at universities and biopharmaceutical companies. These research-only products generally can be marketed without regulatory (FDA) approval, and are therefore relatively near-term business opportunities when compared to human therapeutic products. We may also initiate development programs for human therapeutic applications if sufficient capital becomes available to us or through joint efforts with industry partners.

BioTime is leveraging its product development strategy on two key technology platforms:
 

  • • An advanced iPS technology allowing the transformation of human cells of the body back to a primordial stem cell state equivalent to embryonic stem cells. Using this technology with patient specific stem cells, rather than stem cells derived from embryos donated by unrelated people, may reduce the incidence of rejection of tissue grafts.
     
  • ACTCellerate™ technology that permits the generation of scalable and highly purified cells of the human body.

See this link for more information:  http://www.biotimeinc.com/aboutBT.htm

 

 

 

 

 

 

Management: 

http://www.biotimeinc.com/management.htm
 

 

Dr. Michael West, CEO

Dr. West is the Chief Executive Officer of BioTime, Inc. (NYSE AMEX: BTIM) and Embryome Sciences, Inc. of Alameda, California. The Companies are focused on developing an array of research and therapeutic products using human embryonic stem cell technology. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular aging. He has focused his academic and business career on the application of developmental biology to the age-related degenerative disease. He was the Founder of Geron Corporation of Menlo Park, California (Nasdaq: GERN) and from 1990 to 1998 he was a Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998 he organized and managed the research collaboration between Geron and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells. From 1998 to 2007 he was President and Chief Scientific Officer at Advanced Cell Technology, Inc. (OTCBB: ACTC) where he managed programs in animal cloning, human somatic cell nuclear transfer, retinal differentiation, and ACTCellerate, a technology for the multiplex derivation and characterization of clonal human embryonic progenitor cell lines. 

Dr. West's complete CV and background on his research interests are available online at: http://www.michaelwest.org/


 

 

 

 

Recent News: 

http://www.b2i.us/profiles/investor/ResLibrary2.asp?BzID=1152&GoTopage=&Category=1802&t=
 

 

http://finance.yahoo.com/q/h?s=BTX+Headlines

 

Subsidiaries
http://www.biotimeinc.com/subsidiaries/


 

 

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0000876343&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

 

Transfer Agent:

American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038

 

Investor Relations:

Judith Segall

VP of Administration, Corporate Secretary

isegall@biotimemail.com

Phone:  510.521.3390 ext 301

 

 

 


 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

Also, keep in mind that moderators may or may not have a position in said stock.   Being a moderator isn't a sign of endorsement.

  

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:
http://investorshub.advfn.com/boards/complex_terms.asp

 

SureTrader
BTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
BTX News: Current Report Filing (8-k) 02/22/2018 07:01:24 AM
BTX News: BioTime Appoints Cavan Redmond to Its Board of Directors 02/22/2018 07:00:00 AM
BTX News: Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 02/15/2018 07:00:00 AM
BTX News: BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018 02/07/2018 07:00:00 AM
BTX News: Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference 01/29/2018 07:00:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#811   Item 5.02 - Departure of Directors or Certain ahab333 02/22/18 09:35:27 AM
#810   Biotime's Board addition: ahab333 02/22/18 09:32:30 AM
#809   Thanks. Yes, Mike is not sensationalist. He will downplay anything DeepDive 02/15/18 01:05:22 PM
#808   Data from BioTime's OpRegen® and Vision Restoration Programs terry hallinan 02/15/18 11:17:29 AM
#807   New http://youtu.be/BJsOPiBsQPg DeepDive 02/05/18 01:56:22 PM
#806   no argument here DeepDive. I am not ahab333 02/05/18 11:08:26 AM
#805   These kind for valuations always make me laugh. terry hallinan 02/03/18 06:47:26 AM
#804   These kind for valuations always make me laugh. DeepDive 02/03/18 05:46:25 AM
#803   Lake Street boys up target price for BTX ahab333 02/02/18 10:26:39 AM
#802   Earn money? BTX will: Renevia(®) successfully met the primary sokol 01/30/18 08:00:20 AM
#801   At some point in the future they have terry hallinan 01/29/18 06:22:01 PM
#800   Patrick Cox, who has a free report at pymadams 01/29/18 04:51:20 PM
#799   the only thing I see is todays new release. newguy49 01/29/18 04:10:47 PM
#798   Great day here on 5X normal volume too. Perkin78 01/29/18 03:28:44 PM
#797   are they EVER going to spin off ageX? newguy49 01/29/18 02:08:34 PM
#796   Shares of BTX are up $1.00 since 12/29/17 ahab333 01/29/18 12:31:50 PM
#795   Nice punch through the 2.80 - 2.88 area ahab333 01/26/18 03:56:34 PM
#794   I too thought there would be more information ahab333 01/22/18 10:49:55 AM
#793   BioTime Announces Clinical and Corporate Milestone Targets for terry hallinan 01/22/18 09:06:35 AM
#792   I didn't see this on the BIOTime website. pymadams 01/15/18 11:52:56 AM
#791   Oddly I also thought ownership of AST's telomerase terry hallinan 01/10/18 11:31:27 AM
#790   Thanks, Dive, for the slides. terry hallinan 01/10/18 10:53:47 AM
#789   And BTX's newest set of slides. DeepDive 01/10/18 06:25:41 AM
#788   New Presentation slides. DeepDive 01/10/18 06:04:08 AM
#787   Amazing. They’re using Computing power to find known molecules DeepDive 01/10/18 02:41:19 AM
#786   Wise. Very wise. DeepDive 01/10/18 02:36:05 AM
#785   Thanks Sokol, I do my DD on all ahab333 01/09/18 01:25:10 PM
#784   See this: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&o sokol 01/08/18 08:47:14 PM
#783   The plan is for owners of BTX to sokol 01/08/18 08:40:25 PM
#782   I remember reading that AgeX was going to ahab333 01/08/18 03:35:04 PM
#781   HOD so far was 2.80 on pretty good ahab333 01/08/18 01:51:40 PM
#780   How far under the radar does this stock fly? terry hallinan 01/07/18 10:46:56 PM
#779   Perhaps because the survey calls for 2018. we DeepDive 01/05/18 03:30:36 PM
#778   Cinci, if that's the case, and we REALLY ahab333 01/05/18 02:35:30 PM
#777   Noticed the Silicon Investor website Biotech Charity Contest Cincinnatus 01/05/18 01:20:18 PM
#776   Terry, that's pretty much what I was looking pymadams 01/03/18 11:41:45 AM
#775   Terry, that's pretty much what I was looking pymadams 01/03/18 11:41:44 AM
#774   What was the IFATS data. terry hallinan 01/02/18 07:08:46 PM
#773   More information on the newly-published peer-reviewed study: ahab333 01/02/18 10:27:48 AM
#772   AGEX VIDEO OUT. WATCH IT. DeepDive 01/02/18 09:30:07 AM
#771   What was the IFATS data. pymadams 01/02/18 06:03:20 AM
#770   Happy New year everyone and once again, another ahab333 12/29/17 01:32:31 PM
#769   It's been very quiet here like ehco echooooo ahab333 12/21/17 10:24:34 AM
#768   New slides BioTime (BTX) Presents At The 10th Annual DeepDive 12/06/17 01:13:45 PM
#767   Round table panel on the path going forward ahab333 12/04/17 01:44:01 PM
#766   I am very curious to see how they terry hallinan 12/01/17 10:46:29 AM
#765   Very true DeepDive. Bio time has so ahab333 12/01/17 10:29:33 AM
#764   Thanks Ahab. I am very curious to see how DeepDive 12/01/17 06:10:17 AM
#763   Renevia program to be presented today in Europe: ahab333 11/30/17 11:49:21 AM
#762   I was thinking how great and liberating this terry hallinan 11/27/17 08:00:06 PM
PostSubject